NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis $2.49 -0.01 (-0.40%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.01 (+0.40%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Cellectar Biosciences Stock (NASDAQ:CLRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cellectar Biosciences alerts:Sign Up Key Stats Today's Range$2.46▼$2.5750-Day Range$2.23▼$3.5352-Week Range$2.20▼$10.19Volume36,385 shsAverage Volume157,723 shsMarket Capitalization$19.90 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingModerate Buy Company Overview Cellectar Biosciences, Inc. is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy. Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma. In addition to its therapeutic pipeline, Cellectar has developed CLR 1501 and CLR 1502, fluorescent and near‐infrared imaging probes that enhance intraoperative tumor detection and surgical guidance. These imaging agents are intended to help surgeons distinguish cancerous tissue from healthy tissue in real time. Founded in 2007 and headquartered in Madison, Wisconsin, Cellectar Biosciences conducts its research and development primarily in the United States. Preclinical and clinical studies have demonstrated the selective uptake and prolonged retention of its PDC compounds in tumor cells, supporting the potential of its platform across a range of oncologic indications. The company collaborates with academic centers and contract research organizations to advance its clinical programs. Under the leadership of President and Chief Executive Officer Will Berry, Cellectar Biosciences is advancing its pipeline and engaging with regulatory agencies to support future product commercialization. The company continues to explore strategic partnerships and funding opportunities to further develop its PDC technology for both therapeutic and diagnostic applications in oncology.AI Generated. May Contain Errors. Read More Cellectar Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreCLRB MarketRank™: Cellectar Biosciences scored higher than 84% of companies evaluated by MarketBeat, and ranked 95th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCellectar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCellectar Biosciences has a consensus price target of $11.00, representing about 341.8% upside from its current price of $2.49.Amount of Analyst CoverageCellectar Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Cellectar Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($2.34) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectar Biosciences has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cellectar Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.32% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 1.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 66.80%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment0.37 News SentimentCellectar Biosciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cellectar Biosciences this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for CLRB on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Cellectar Biosciences in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $49,997.00 in company stock, which represents 0.2513% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,997.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders2.58% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by Institutions16.41% of the stock of Cellectar Biosciences is held by institutions.Read more about Cellectar Biosciences' insider trading history. Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLRB Stock News HeadlinesCellectar Biosciences (NASDAQ:CLRB) Upgraded at Wall Street ZenJune 20, 2026 | americanbankingnews.comCellectar Biosciences (NASDAQ:CLRB) Share Price Crosses Below 200 Day Moving Average - What's Next?June 19, 2026 | americanbankingnews.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.June 24 at 1:00 AM | Chaikin Analytics (Ad)Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society ...June 1, 2026 | finance.yahoo.comCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual MeetingJune 1, 2026 | globenewswire.comCellectar Biosciences (CLRB) price target decreased by 25.00% to 10.71May 14, 2026 | msn.comCellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...May 14, 2026 | finance.yahoo.comCellectar plans Phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027May 14, 2026 | seekingalpha.comSee More Headlines CLRB Stock Analysis - Frequently Asked Questions How have CLRB shares performed this year? Cellectar Biosciences' stock was trading at $2.95 at the beginning of 2026. Since then, CLRB stock has decreased by 15.6% and is now trading at $2.49. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $0.56. Read the conference call transcript. When did Cellectar Biosciences' stock split? Shares of Cellectar Biosciences reverse split before market open on Friday, July 22nd 2022.The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Cellectar Biosciences' major shareholders? Top institutional investors of Cellectar Biosciences include Sequoia Financial Advisors LLC (0.44%). Insiders that own company stock include Jarrod Longcor, James V Caruso, Chad J Kolean and John Neis. View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellectar Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), HudBay Minerals (HBM), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and Company Calendar Last Earnings5/14/2026Today6/24/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CLRB's financial health is in the Red zone, according to TradeSmith. CLRB has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CLRB CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees10Year FoundedN/APrice Target and Rating Average Price Target for Cellectar Biosciences$11.00 High Price Target$11.00 Low Price Target$11.00 Potential Upside/Downside+341.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($6.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-349.24% Return on Assets-153.18% Debt Debt-to-Equity RatioN/A Current Ratio1.90 Quick Ratio1.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.89 per share Price / Book1.32Miscellaneous Outstanding Shares7,990,000Free Float7,786,000Market Cap$19.90 million OptionableNo Data Beta0.52 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CLRB) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFirm That Predicted 2008, 2020, 2022: Right Now Looks WorseThe firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...TradeSmith | SponsoredThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...Golden Portfolio | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellectar Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
